Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Niels Seersholm (Copenhagen, Denmark), Niels Seersholm, Robert Sandhaus, Kenneth R. Chapman, Jonathan Burdon, Eeva Piitulainen, James Stocks, Michael Tortorici, Tanja Rosenberg, Oliver Vit, Martin Bexon, Jonathan Edelman, N. Gerard McElvaney. Safety of bi-weekly infusion of A1-PI augmentation therapy in RAPID. Eur Respir J 2015; 46: Suppl. 59, 999

Member's Comments

No comment yet.

Related content which might interest you: Long-term efficacy of A1-PI therapy in RAPID and its extension study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 LATE-BREAKING ABSTRACT: Long-term efficacy of A1-PI therapy in RAPID and RAPID extension trials Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 Integrated safety across six clinical trials of alpha-1 augmentation therapy Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Safety of biweekly a1-antitrypsin treatment in the RAPID programme Source: Eur Respir J, 52 (5) 1800897; 10.1183/13993003.00897-2018 Year: 2018 Safety and tolerability of acute dosing of beta-blockers in asthma Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Management of selexipag interruptions in the GRIPHON study Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Pharmacological treatment of COPD in the on-sint cohort Source: International Congress 2014 – COPD exacerbations Year: 2014 One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Safety and effectiveness of indacaterol in Korean COPD patients: A post-marketing surveillance (PMS) study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Treatment with low-dose everolimus in patients with sporadic lymphangioleiomyomatosis (LAM) Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS) Source: International Congress 2014 – Asthma and COPD management Year: 2014 Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients Source: International Congress 2014 – Asthma and COPD management Year: 2014 Combination therapy of ICSs/LABAs plus montelucastin patients with severe asthma Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015 Evaluation of methotrexate in the treatment of severe asthma Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Tolerability of different dosing regimens of roflumilast in severe COPD (OPTIMIZE) Source: International Congress 2016 – Pharmacological management of COPD Year: 2016